Why Pet Veterinary Diet Market Will Hit $59.8B by 2034

The Global Pet Veterinary Diet Market reached $28.87 billion in 2025 and is projected to expand to $59.8 billion by 2034, registering a 8.42% CAGR. This growth outpaces the broader Pet Food Market, which is forecast to grow at 5.1% over the same period. Therapeutic nutrition now accounts for 12.4% of total pet food revenue, up from 9.8% in 2020. The Veterinary Diet Market benefits from structural demand: 68% of dog-owning households and 54% of cat-owning households in North America reported at least one chronic condition requiring dietary management in 2024.

Momentum is concentrated in three areas. First, veterinary prescription channels remain the primary route to market, with 72% of revenue flowing through clinics and veterinary pharmacies. Second, e-commerce is accelerating; the Online Pet Veterinary Diet Market grew 18.7% year-over-year in 2024, although it still represents only 21% of total category sales. Third, product innovation targets specific conditions. The Pet Renal Diet Market and Pet Digestive Sensitivity Diet Market together account for 44% of therapeutic diet revenue. The Pet Diabetes Diet Market is smaller at 11% but expanding at 9.3% CAGR due to rising feline diabetes diagnoses.

Macro drivers include pet humanization, where owners treat animals as family members and accept premium prices. In the United States, average annual spending on veterinary diets per pet reached $312 in 2024, up from $248 in 2020. Tele-veterinary platforms increased prescription diet authorizations by 27% between 2022 and 2024. However, premium pricing limits mass adoption: a 10-kg bag of renal diet costs $89 on average, compared to $42 for standard adult dog food. This price gap restricts penetration in price-sensitive markets such as Brazil, Mexico, and India.

Strategic takeaways: manufacturers should prioritize condition-specific formulations with clinical evidence, invest in subscription models tied to tele-vet consultations, and expand manufacturing capacity in Asia-Pacific. The Dog Veterinary Diet Market remains the largest pet-type segment at 63% share, but the Cat Veterinary Diet Market is growing faster at 10.2% CAGR because feline chronic kidney disease prevalence is rising. The next five years will favor vendors that combine veterinary credibility with digital distribution.

Digestive Sensitivity is the largest sub-product in the Global Pet Veterinary Diet Market, generating 26.4% of total revenue in 2025, equivalent to $7.62 billion. This segment includes diets for acute and chronic gastroenteritis, food intolerance, pancreatitis, and fiber-responsive conditions. Its share has expanded from 23.1% in 2020, driven by higher diagnosis rates and broader veterinary acceptance of hydrolyzed protein and prebiotic formulations. The Pet Digestive Sensitivity Diet Market is forecast to grow at 9.1% CAGR through 2034, faster than the overall market.

Within digestive sensitivity, hydrolyzed protein diets represent 41% of segment revenue. These products use small peptide fractions from chicken, soy, or feather hydrolysate. The Animal Protein Hydrolysate Market is a critical upstream input, with prices rising 14% between 2022 and 2024 due to limited rendering capacity and higher raw material costs. The second-largest sub-category is fiber-responsive diets at 29%, followed by probiotic-fortified diets at 18%. Probiotic strains such as Enterococcus faecium and Bacillus subtilis are increasingly included in daily therapeutic formulas.

The Pet Renal Diet Market holds a 19.8% share of total market revenue, centered on phosphorus-restricted and protein-controlled formulas for chronic kidney disease. Renal diets are heavily prescribed for aging cats; 34% of cats over 10 years old receive a renal diet in developed markets. The Pet Diabetes Diet Market accounts for 11.2% and is expanding due to high-protein, low-carbohydrate formulations for feline diabetes. The Pet Oral Care Diet Market represents 8.7%, relying on kibble geometry and polyphosphate coatings to reduce tartar.

Digestive sensitivity faces margin pressure from two directions. First, ingredient inflation for hydrolyzed proteins and omega-3 fatty acids raised cost of goods sold by 8.4% in 2023. Second, veterinary clinic consolidation, led by Mars Veterinary Health and National Veterinary Associates, gives large buyers more negotiating power. Vendors are responding with direct-to-consumer subscriptions and veterinary-only loyalty programs. The Dog Veterinary Diet Market commands 63% of all therapeutic diet revenue, but the Cat Veterinary Diet Market is growing at 10.2% CAGR, making feline digestive and renal products the fastest-growing pocket. Share in digestive sensitivity is likely to remain stable rather than expand sharply, as renal and diabetes segments gain relative weight by 2030.

1. Chronic pet disease prevalence: 59% of dogs and 52% of cats in the United States are overweight or obese, according to the Association for Pet Obesity Prevention. Obesity drives diabetes, arthritis, and renal disease, directly expanding the Pet Diabetes Diet Market and Pet Renal Diet Market.
2. Tele-veterinary prescription platforms: Virtual vet visits grew from 4.7 million in 2021 to 12.3 million in 2024 in North America. These platforms authorize therapeutic diets in 41% of consultations, up from 19% in 2021.
3. Microbiome-targeted formulations: Post-biotic and psychobiotic ingredients now appear in 17% of new veterinary diet launches, up from 6% in 2020. Clinical trials show 22% reduction in GI relapse for hydrolyzed diets with added probiotics.
4. Pet humanization and premium spending: Global pet care spending reached $320 billion in 2024. Owners who buy veterinary diets spend 2.8x more on pet food than non-prescription buyers.

• Premium pricing limits mass adoption: A 7-kg bag of veterinary renal diet costs $72 in the EU, compared to $28 for standard adult food. In India and Brazil, price sensitivity keeps veterinary diet penetration below 8% of pet food sales.
• Stringent prescription and labeling regulations: FDA CVM requires therapeutic diets to meet AAFCO nutrient profiles or have veterinary prescription labeling. In the EU, FEDIAF guidelines demand clinical substantiation for disease claims, adding 8–14 months to launch timelines.
• Veterinary clinic consolidation squeezing shelf space: The top five veterinary corporate groups control 38% of U.S. companion animal clinics. They favor three to four diet brands, reducing shelf availability for smaller vendors.
• Sustainability scrutiny: 64% of European pet owners consider environmental impact when buying pet food. Veterinary diets often use animal protein and single-use packaging, creating reputational risk.

• Mars, Incorporated: Operates Royal Canin and Mars Veterinary Health, integrating diet manufacturing with the world's largest veterinary clinic network. Royal Canin's renal and digestive portfolios hold an estimated 28% share of global veterinary diet revenue.
• Nestlé Purina PetCare (Nestlé S.A.): Purina Pro Plan Veterinary Diets covers renal, gastrointestinal, and diabetes categories. The company invested $550 million in a new pet food facility in Ohio in 2023 to increase therapeutic diet capacity.
• Colgate-Palmolive Company (Hill’s Pet Nutrition, Inc.): Hill's Prescription Diet leads in renal and oral care segments, with veterinary clinic penetration above 70% in the United States. Hill's reported 7.2% organic sales growth in its pet nutrition division in 2024.
• General Mills, Inc. (Blue Buffalo Pet Products, Inc.): Blue Buffalo entered veterinary diets through its BLUE Natural Veterinary Diet line, focusing on digestive and skin conditions. The company leverages retail channels but has limited veterinary clinic presence.
• Schell & Kampeter, Inc. (Diamond Pet Foods): Supplies private-label and contract-manufactured veterinary diets for clinic chains. Its scale in dry extruded kibble provides cost advantages but low brand recognition.
• Wellness Pet Company (Clearlake Capital Group, L.P.): Offers veterinary-approved digestive and weight management diets. The company expanded its online subscription program by 34% in 2024.
• Farmina Pet Foods Holding: Italian manufacturer with strong presence in Europe for renal and urinary diets. Farmina uses high-protein, low-grain formulations and sells through veterinary specialists.
• Affinity Petcare S.A. (Agrolimen, S.A.): Spanish pet food group with veterinary diet lines for dogs and cats in Southern Europe. Affinity acquired a veterinary distribution platform in 2023 to control clinic access.
• Unicharm Corporation: Japanese company with veterinary diets for aging cats, particularly renal and oral care. Unicharm leverages its pet hygiene and litter business for cross-selling.
• Covetrus, Inc. (CD&R and TPG Joint Venture): Distributes veterinary diets and prescription foods across North America and Europe. Its online pharmacy platform processes over 2 million veterinary diet orders annually.

• January 2024: Hill's Pet Nutrition launched Prescription Diet k/d + Mobility, combining renal support with joint health for aging cats. The product targets the 34% of senior cats with chronic kidney disease.
• March 2024: Mars Petcare opened a $200 million Royal Canin facility in Poland dedicated to veterinary diets for European markets. The plant added 45,000 tons of annual renal and digestive capacity.
• June 2024: Nestlé Purina acquired a veterinary telehealth platform to bundle diet prescriptions with virtual consultations. The deal aimed to capture the 41% of tele-vet visits that result in therapeutic diet recommendations.
• September 2024: Farmina Pet Foods launched a new hydrolyzed protein line for dogs with food allergies. The company reported 16% revenue growth in its veterinary channel for 2024.
• November 2024: Covetrus expanded its online veterinary diet subscription service to five new European countries. The platform now serves over 12,000 veterinary clinics.
• February 2025: Blue Buffalo entered the veterinary renal diet category with a retail-exclusive formula. The launch marks General Mills' first direct challenge to Hill's and Royal Canin in therapeutic nutrition.

North America is the largest region with 37% revenue share, valued at $10.68 billion in 2025. The regional CAGR is 7.1%, slower than the global average because the market is mature. Primary demand driver is high pet insurance penetration, which covers prescription diets for 28% of insured pets. Regulatory conditions are strict: FDA CVM enforces AAFCO profiles, and state veterinary boards require prescriptions for therapeutic claims.

Europe holds 27% share, or $7.79 billion, with a CAGR of 7.8%. The region's growth is driven by premiumization in Germany, France, and the UK, where 44% of pet owners buy veterinary diets at least once per year. FEDIAF guidelines govern labeling. The EU's Farm to Fork strategy encourages alternative proteins, which affects hydrolyzed ingredient sourcing.

Asia-Pacific is the fastest-growing region at 11.2% CAGR, with 22% share ($6.35 billion in 2025). Japan and South Korea lead in renal diets for aging cats, while China and India show rapid dog ownership growth. Regulatory frameworks are fragmented: Japan's MAFF and China's MARA require separate registrations. The Cat Veterinary Diet Market in Japan grew 13.4% in 2024.

South America and the Middle East & Africa together represent 14% share, valued at $4.04 billion. Brazil dominates South America with 61% regional revenue. Growth is constrained by price sensitivity but supported by rising urbanization. Local regulations follow Mercosur and GCC standards, with limited enforcement of prescription-only status. The fastest-growing market overall is Asia-Pacific; the most mature is North America.

Veterinary diets face distinct regulatory pathways from conventional pet food. In the United States, the FDA Center for Veterinary Medicine (CVM) oversees therapeutic claims. Products must either meet AAFCO nutrient profiles or carry a veterinary prescription label. In 2024, CVM issued draft guidance on post-biotic ingredients, requiring safety data for live microbial strains. The agency also increased inspections of imported hydrolyzed protein facilities by 22% in 2024.

Europe operates under FEDIAF Nutritional Guidelines and EU Regulation 767/2009 on feed marketing. The European Food Safety Authority (EFSA) evaluates novel ingredients. In 2023, EFSA approved a new insect protein for pet food, opening a path for hypoallergenic diets. REACH regulations affect packaging chemicals, and the EU's Packaging and Packaging Waste Regulation will require 30% recycled content by 2030.

Asia-Pacific has no unified framework. Japan's Ministry of Agriculture, Forestry and Fisheries (MAFF) requires efficacy data for veterinary diets. China's Ministry of Agriculture and Rural Affairs (MARA) mandates registration for imported therapeutic diets, a process taking 12–18 months. India's FSSAI classifies veterinary diets as animal feed, with lower scrutiny. Compliance costs range from $45,000 to $180,000 per SKU for multi-country launches.

Upstream inputs for veterinary diets include animal protein hydrolysates, chicken meal, pea protein, corn gluten meal, fish oil, taurine, and vitamin premixes. The Animal Protein Hydrolysate Market is concentrated among five global suppliers, creating single-source risk. Hydrolyzed chicken liver and feather meal prices rose 14% in 2024 due to rendering capacity constraints. Fish oil, a source of EPA and DHA, saw prices increase 22% in 2022 before stabilizing in 2024.

Sourcing risks include disease outbreaks. The 2022 avian influenza outbreak reduced chicken meal availability by 9% in North America and Europe. The 2021 palm oil shortage affected fat coatings. For renal diets, phosphorus binders and restricted-protein ingredients rely on whey protein isolate and egg white, both subject to dairy and egg price cycles. Vitamin premixes depend on Chinese and European suppliers; a 2023 vitamin A shortage raised prices 31%.

Manufacturers are diversifying with insect protein, algal omega-3, and fermentation-derived amino acids. These alternatives remain 2–3x more expensive than conventional proteins. Logistics disruptions in the Red Sea in 2024 added 12–18 days to European-Asian shipments of vitamin premixes. Overall, supply chain volatility is expected to persist, driving vertical integration among large vendors and long-term contracts with hydrolysate suppliers.

• 1. Sub Product
  • 1.1. Diabetes
  • 1.2. Digestive Sensitivity
  • 1.3. Oral Care Diets
  • 1.4. Renal
  • 1.5. More
• 2. by Pets
  • 2.1. Cats
  • 2.2. Dogs
  • 2.3. Other Pets
• 3. by Distribution Channel
  • 3.1. Convenience Stores
  • 3.2. Online Channel
  • 3.3. More

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific